Nasdaq

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a ...
Seeking Alpha

ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab ...
Cure Today

Enhertu Tolerable in Patients With HER2-Low Metastatic Breast Cancer

Toxicity-related discontinuation occurred in 15%, largely ILD/pneumonitis, mirroring DESTINY-Breast04, supporting generalizability of trastuzumab deruxtecan tolerability to community practice ...
Seeking Alpha

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in ...

Second positive Phase III trial of AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in ...